Jagsonpal Pharmaceuticals vs Peers
- Market cap
- ₹1,522 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹163.62 – ₹306.79
Jagsonpal Pharmaceuticals ranks 1st by market capitalisation among 1 Drug Manufacturers - Specialty & Generic companies tracked by ATS. Its largest peers are Jagsonpal Pharmaceuticals. Its P/E of 22.5 compares with a peer median of 22.5.
Jagsonpal Pharmaceuticals vs Drug Manufacturers - Specialty & Generic peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Jagsonpal Pharmaceuticals | 227.25 | -3.46% | 1,522 | 22.5 | 2.85 | 14.5% | +18.5% |
| Jagsonpal Pharmaceuticals | 227.25 | -3.46% | 1,522 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Jagsonpal Pharmaceuticals peer comparison — frequently asked questions
Who are Jagsonpal Pharmaceuticals' competitors?
Jagsonpal Pharmaceuticals' listed peers in Drug Manufacturers - Specialty & Generic include Jagsonpal Pharmaceuticals, ranked here by market capitalisation.
How does Jagsonpal Pharmaceuticals' P/E compare with its peers?
Jagsonpal Pharmaceuticals trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - Specialty & Generic peers shown.
Which is the largest company among Jagsonpal Pharmaceuticals' peers?
By market capitalisation, the largest company in the group is Jagsonpal Pharmaceuticals at ₹1,522 crore, against ₹1,522 crore for Jagsonpal Pharmaceuticals.
Same Data For Peers
Trade Jagsonpal Pharmaceuticals With ATS
Track JAGSNPHARM live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.